Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 13/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.39 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.39 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23682688 | 0.84 | HPGDS (0.48) | HPGDSKDM4EMEN1NPC1GLA | |
| SCHEMBL25696841 | 0.79 | ABL1 (0.39) | HPGDSABL1KDM4EMEN1NPC1 | |
| SCHEMBL23815551 | 0.78 | HPGDS (0.40) | HPGDS | |
| SCHEMBL4145082 | 0.74 | MGAM (0.65) | HPGDSKDM4EMEN1NPC1MAPT | |
| SCHEMBL16981012 | 0.73 | RXFP1 (0.47) | MEN1MAPTRAB9AKMT2AHCAR3 | |
| SCHEMBL25049716 | 0.71 | HPGDS (0.49) | HPGDSKDM4EMEN1NPC1GLA | |
| SCHEMBL23718016 | 0.71 | HPGDS (0.42) | HPGDS | |
| SCHEMBL23683055 | 0.70 | HPGDS (0.41) | HPGDS | |
| SCHEMBL24239879 | 0.70 | RXFP1 (0.36) | MEN1NPC1RAB9AKMT2AHCAR3 | |
| SCHEMBL17967325 | 0.70 | KDM4E (0.62) | HPGDSKDM4EMEN1NPC1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | HPGDS 4323/4885ABL1 4637/4885KDM4E 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.